

UNITED STATES PATENT AND TRADEMARK OFFICE  

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SANDOZ INC.,  
Petitioner,

v.

ELI LILLY AND COMPANY,  
Patent Owner.

Case No. IPR2016-00318  
Patent No. 7,772,209

**PATENT OWNER'S RESPONSE**

## TABLE OF CONTENTS

I.	Background.....	4
A.	Antifolates and Folates .....	4
B.	Antifolates and Vitamin B <sub>12</sub> .....	6
C.	Homocysteine and MMA.....	7
D.	Antifolate Research .....	8
E.	Development of the Claimed Invention .....	9
F.	The District Court Litigation.....	12
II.	Critical Date of the '209 Patent .....	13
III.	The Person of Ordinary Skill in the Art .....	13
IV.	Claim Construction – “Patient” .....	14
V.	Sandoz Has Failed to Demonstrate That the Challenged Claims Are Obvious.....	17
A.	The POSA Would Not Have Had Reason To Use Folic Acid Pretreatment with Pemetrexed .....	18
1.	The POSA Would Have Avoided Folic Acid Pretreatment Because It Would Have Lowered Pemetrexed’s Efficacy .....	19
2.	The POSA Would Have Considered Pemetrexed’s Toxicities to be Tolerable and Manageable.....	21
3.	The Hammond Abstracts, Worzalla, and the '974 Patent Would Not Have Given the POSA a Reason To Pretreat with Folic Acid.....	23

B.	The POSA Would Not Had Reason To Pretreat Pemetrexed Patients with Vitamin B <sub>12</sub> .....	34
1.	The POSA Would Have Expected that Vitamin B <sub>12</sub> Pretreatment Would Decrease Pemetrexed’s Efficacy .....	35
2.	Niyikiza I and Calvert I Do Not Support Adding Vitamin B <sub>12</sub> to the Worzalla and Hammond Regimes.....	37
3.	The POSA Would Not Have Used Folic Acid and Vitamin B <sub>12</sub> Pretreatment Based on EP 005 .....	42
4.	The POSA would not have been concerned about a “masked” vitamin B <sub>12</sub> deficiency in cancer patients .....	44
5.	Sandoz’s Additional References Do Not Teach Vitamin B <sub>12</sub> Pretreatment .....	46
C.	The POSA Would Not Use the Doses and Schedules Claimed in the ’209 Patent .....	49
1.	Claims 9, 10, 12, 13-15, and 17-22 Would Not Have Been Obvious Because the POSA Would Not Simultaneously Lower the Folic Acid Dose in Hammond and Add Vitamin B <sub>12</sub> to the Regimen .....	50
2.	The Additional Dosing and Scheduling Limitations Would Not Have Been Obvious .....	51
VI.	Secondary Considerations of Non-Obviousness Support Patentability .....	57

**TABLE OF AUTHORITIES**

**FEDERAL CASES**

*Eli Lilly & Co. v. Teva Parenteral Medicines, et al.*, Case No. 1:10-cv-1376-TWP-DKL (S.D. Indiana) ..... 12

*Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., et al.*, No. 2015-2067 (Fed. Cir.)..... 13

*In re Applied Materials, Inc.*, 692 F.3d 1289 (Fed. Cir. 2012) ..... 56

*Kinetic Concepts, Inc. v. Smith & Nephew, Inc.*, 688 F.3d 1342 (Fed. Cir. 2012) ..... 18, 41

*KSR Int’l Co. v. Teleflex Inc.*, 550 U.S. 398 (2007) ..... 18, 56

*Leo Pharm. Prod., Ltd. v. Rea*, 726 F.3d 1346 (Fed. Cir. 2013) ..... 57

*Medichem S.A. v. Rolabo*, 437 F.3d 1157 (Fed. Cir. 2006)..... 27

*Phillips v. AWH Corp.*, 415 F.3d 1303 (Fed Cir. 2005) (en banc) ..... 15

*Princeton Biochemicals, Inc. v. Beckman Coulter, Inc.*, 411 F.3d 1332 (Fed. Cir. 2005)..... 27

*Spectralytics, Inc. v. Cordis Corp.*, 649 F.3d 1336 (Fed. Cir. 2011)..... 29

*Syntex (U.S.A.) LLC v. Apotex, Inc.*, 407 F.3d 1371 (Fed. Cir. 2005)..... 27

*Thorner v. Sony Computer Entm’t Am. LLC*, 669 F.3d 1362 (Fed. Cir. 2012) ..... 16

*WBIP, LLC v. Kohler Co.*, —F.3d—, 2016 WL 3902668 (Fed. Cir. Jul. 19, 2016)..... 57

**OTHER AUTHORITIES**

37 C.F.R. § 42.100(b) ..... 14

35 U.S.C. § 103(a) ..... 17

IPR2016-00237, Paper 1 ..... 15

IPR2016-00240, Paper 1 ..... 15  
U.S. Patent No. 7,772,209.....passim  
*Wall Street Journal* ..... 1.58

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.